November 2nd, 2021Fluidx Medical’s GPX Embolic Device Releases Initial Results for Oncology Drug Delivery
Fluidx Medical Technology announced that a next-generation, doxorubicin-loaded GPX Embolic Device was featured at the recent Symposium on Clinical Interventional Oncology (CIO) Conference highlighting the technology’s potential for oncology drug...
August 24th, 2021Fluidx Medical’s GPX™ Embolic Device Use for Tumor Treatments Chosen for “BEST of GEST” Embolization Program at the Annual GEST Meeting
Fluidx Medical Technology’s GPX Embolic Device was selected for a Global Embolization Oncology Symposium Technologies (“GEST”) “BEST of GEST” session highlighting the technology’s...
March 30th, 2021New Embolic Device Blocks Vessels Feeding Malignant Tumors
Fluidx Medical’s GPX™ Embolic Device Demonstrates Versatility and Control in Oncology Clinical Use
Fluidx Medical Technology, Inc. released details on clinical use of their GPX Embolic Device for blocking flow to small microvasculature and large tumor feeding...
February 2nd, 2021GPX Embolic Device Showcased at Leipzig Interventional Course (LINC) for Interventional Oncology Embolizations
Fluidx Medical Technology announced GPX Embolic Device first patient use cases were presented at the Leipzig Interventional Course (LINC) in Leipzig, Germany...
Novel Interventional Oncology Embolization Device Successfully Used in Trans-Radial Access Procedures for Tumor Devascularization
November 24, 2020 – Fluidx Medical Technology reported successful patient use of the GPX Embolic Device to therapeutically devascularize, or block blood supply to, a tumor.
“We are impressed with the...
